Medical News: EULAR: Abatacept Efficacy in Juvenile Arthritis Lasts Beyond Two Years - in Meeting Coverage, EULAR from MedPage Today
Links shared publicly online about this topic.
- 1,963total visits
Medical News: EULAR: Abatacept Efficacy in Juvenile Arthritis Lasts Beyond Two Years - in Meeting Coverage, EULAR from MedPage Today
COPENHAGEN -- Children with juvenile idiopathic arthritis continued to respond to abatacept (Orencia) for up to 30 months, researchers said here.
View full resource at medpagetoday.com
Tags: Arthritis, Rheumatoid Arthritis Medication, Juvenile Rheumatoid Arthritis, Clinical Trial, Children's Health, Orencia, Rheumatology
Most Recently Shared on June 17, 2009 at 7:40 pm By:
RHEUMATOLOGY• EULAR: Abatacept Efficacy in Juvenile Arthritis Lasts Beyond Two Years (CME/CE) http://tinyurl.com/knbkgg
Advertisement
